BIIB $349.98 +1.50 (0.43%)
Ideas, Updates & Analysis
Probably the biggest story in the stock market today was Biogen.
Biogen Alzheimer's Drug Success
As a result, the stock was up over 19% today.
Fortunately, I bought a few shares on Fri, Mar 16 at $291.
I bought for several fundamental and technical reasons.
Even though the stock is now close to the 52 week high, which is bullish, I decided to sell today and lock in my profits.
Why did I sell?
Simply put, the stock price is near the top of the trading range I highlighted in my previous post.
From a technical standpoint, that made the decision to sell pretty easy while limiting the emotions of fear and greed.
I mentioned the $350 price level and I sold at $355.
Overall, it was a 22% return.
Obviously, this unexpected big announcement caught everyone by surprise.
Fortunately, it was a positive announcement.
If you are new to stock market investing you should be aware that almost all companies report 4 big announcements every year on publicly disclosed dates.
It is called the earnings announcement.
The earnings announcement can move the stock price quite a bit.
So you don't get caught off guard, I highly recommend using an earnings calendar on a regular basis.
Fri, Jul 6, 2018 BIIB @ $357.48
I bought this stock at $291 in March and I was all set for this thing to run.
It did run.
It ran all the way down to the $257.
In hindsight, I hit the buy button too early.
I was down over 10%.
I was not concerned.
Ok, I was a little concerned.
There was no new bad news, so I held on.
Fortunately, the Earnings release on Tue, Apr 24, 2018 was received very well.
Now the stock is above where I purchased by about $2.
Ok, now I ready to see this thing run.
I am ready to see this stock run up.
How about $320 or higher?
Thu, May 31, 2018 BIIB @ $293.96
While scanning the bear market stocks page, I saw Biogen.
It's a list of stocks that are -20% or more since their 52 week high.
I look for a couple of setups.
1) Charts that show the stock price is moving sideways or "price consolidation".
2) Charts with a significant price drop over the course of a couple days. Sometimes it is a legitimate reaction to bad news, while other times, it is an overreaction to bad news.
The 52 Week High stock price is $370.57 from Fri, Jan 26, 2018.
The stock is down quite a bit down to $291.
The 1 year chart shows a large rapid decline from the recent earnings announcement on Thu, Jan 25, 2018.
So that looks a little scary.
The 5 year chart tells a different story which I have highlighted in yellow.
It shows an uptrend with the stock price currently near support.
Based on the overall trend, this looks like a good time to get in.
If the trend stays intact, the stock could move up to $350 or higher.
Unfortunately, this BIIB does not pay a dividend, but it has a relatively low p/e ratio.
Fri, Mar 16, 2018 BIIB @ $287.62
Biogen Stock Charts
The 5 year and 1 year stock charts are below.
50 Day Moving Average
The 50 Day Moving Average is at $298.44 which is 17.27% below the stock price of $349.98.
200 Day Moving Average
The 200 Day Moving Average is at 305.49 which is 14.56% below the stock price of $349.98.
Because both the 50 DMA and 200 DMA are below the current stock price, this can be considered a bullish technical indicator.
Since the stock price is very far from both moving averages, a price retracement towards the moving averages should not be unexpected.
BIIB Stock Price
Below are a few key dates for the stock price.
Year To Date
The most recent stock price is $349.98.
The Year To Date (YTD) return is +4.73%.
52 Week Low
The 52 Week Low stock price is $249.17 set on Tue, Apr 24, 2018 which is 83 days ago.
The current price per share is 40.46% above the 52 week low.
52 Week High
The 52 Week High stock price is $370.57 set on Fri, Jan 26, 2018 which is 171 days ago.
The current price per share is -5.56% below the 52 week high.
All Time High
The All Time High stock price is $480.18 set on Fri, Mar 20, 2015 which is 1,214 days ago.
The current price per share is -27.11% below the all time high.
Below is the EPS, P/E Ratio and Earnings Date.
The Earnings Per Share (EPS) is $13.99.
The Price To Earnings (P/E) Ratio is 24.91.
Biogen has a relatively low price to earnings ratio compared to the overal S&P 500 average, which is about 25%.
Some investors look for very low p/e stocks with the hopes of investing in an undervalued stock. Of course, this is just one factor to consider.
Stocks can make big percentage moves on the earnings announcement.
Companies announce earnings either before the market open or after the close.
The Earnings Release Date for Biogen Inc was Thu, Jan 25, 2018.
Since this earnings release 172 days ago, the stock price is up by +1.00%.
The most recent Earnings Release Date was on Tue, Apr 24, 2018, which was 83 days ago.
Since this earnings date, the stock price is up by +34.97%.
Below is important Dividend information.
BIIB currently does not pay a dividend.
You may like this list of best dividend stocks of 2018.
Biotech & Pharma Industry
Below are other stocks in the same industry as Biogen.
BIIB Company Profile
Learn more about Biogen.
Biogen Inc is a Health Care stock that trades on the NASDAQ and has a market capitalization of $73.53 Billion.
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
Spend a few minutes browsing the Biogen Inc, web site at http://www.biogen.com.